What is Adherium?
Adherium Limited is at the forefront of respiratory eHealth, specializing in patient adherence, remote monitoring, and data management solutions. Their core technology, the Hailie Smartinhaler, coupled with a robust cloud-based platform, is designed to enhance medication adherence for individuals managing severe asthma and COPD. By integrating telehealth advancements and remote monitoring capabilities, Adherium aims to significantly reduce healthcare expenditures linked to medication non-adherence, benefiting patients, physicians, payers, and healthcare providers alike. The company's strategic focus on improving patient outcomes through technology positions it as a key player in the digital health landscape.
How much funding has Adherium raised?
Adherium has raised a total of $44.9M across 8 funding rounds:
Corporate Investment
$3M
Stock Offering
$25.6M
Share Placement
$5.9M
Debt
$1.8M
Debt
$1.2M
Private Equity
$3.5M
Debt
$3M
Other Financing Round
$900K
Corporate Investment (2015): $3M with participation from AstraZeneca
Stock Issuance/Offering (2015): $25.6M led by Undisclosed
Share Placement (2016): $5.9M supported by Fidelity
Debt (2019): $1.8M featuring Summatix Pty Limited and One Funds Management Limited
Debt (2019): $1.2M backed by Trudell Medical Limited
Private Equity (2020): $3.5M with participation from Undisclosed
Debt (2020): $3M led by Viburnum
Other Financing Round (2025): $900K supported by Trudell Medical and Phillips Asset Management
Key Investors in Adherium
Trudell Medical
Trudell Medical is a company focused on respiratory care, aiming to provide patients worldwide with medical devices and services that improve their lives, including leading brands in respiratory care like AeroChamber® spacers and Aerobika® OPEP devices.
Fidelity
Fidelity Investments is an international provider of financial services and investment resources, assisting individuals and institutions in achieving their financial objectives.
AstraZeneca
AstraZeneca is a global biopharmaceutical company focused on the discovery, development, and commercialization of prescription medicines, particularly in Oncology and BioPharmaceuticals, including areas like Cardiovascular and Respiratory & Immunology.
What's next for Adherium?
With the recent major strategic investment, Adherium is poised for accelerated expansion and further development of its innovative adherence solutions. This capital infusion is expected to fuel advancements in their platform, enhance market penetration, and potentially explore new therapeutic areas or patient populations. The company's trajectory, marked by consistent backing from strategic partners and financial institutions, suggests a strong emphasis on scaling operations and solidifying its position as a leader in remote respiratory care management. Future initiatives will likely focus on leveraging data analytics to provide deeper insights into patient behavior and treatment efficacy, further driving down healthcare costs and improving patient quality of life.
See full Adherium company page
